Marinobufagenin in essential hypertension and primary aldosteronism: a cardiotonic steroid with clinical and diagnostic implications

References

• Bagrov AY, Shapiro JI, Fedorova OV. Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets. Pharmacol Rev 2009;61:9–38
   PubMed Web of Science ®Google Scholar
• Dmitrieva RI, Bagrov AY, Lalli E, et al. Mammalian bufadienolide is synthesized from cholesterol in the adrenal cortex by a pathway that is independent of cholesterol side-chain cleavage. Hypertension 2000;36:442–8
   PubMed Web of Science ®Google Scholar
• Hillyard SD, Lu E, Gonick HC. Further characterization of the natriuretic factor derived from kidney tissue of volume-expanded rats. Effects on short-circuit current and sodium-potassium-adenosine triphosphatase activity. Circ Res 1976;38:250–5
   PubMed Web of Science ®Google Scholar
• Bagrov AY, Fedorova OV. Cardenolide and bufadienolide ligands of the sodium pump. How they work together in NaCl sensitive hypertension. Front Biosci 2005;10:2250–6
   PubMed Web of Science ®Google Scholar
• Ritz E, Tomaschitz A. Aldosterone, a vasculotoxic agent – novel functions for an old hormone. Nephrol Dial Transplant 2009;24:2302–5
   PubMed Web of Science ®Google Scholar
• Tian J, Shidyak A, Periyasamy SM, et al. Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin. Hypertension 2009;54:1313–20
   PubMed Web of Science ®Google Scholar
• Tomaschitz A, Pilz S, Ritz E, et al. Association of plasma aldosterone with cardiovascular mortality in patients with low estimated GFR: the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. Am J Kidney Dis 2011;57:403–14
   PubMed Web of Science ®Google Scholar
• Tomaschitz A, Pilz S, Pieske B, et al. Circulating aldosterone and mortality in female nursing home residents. Exp Gerontol 2013;48:313–18
   PubMed Web of Science ®Google Scholar
• Gonick HC, Ding Y, Vaziri ND, et al. Simultaneous measurement of marinobufagenin, ouabain, and hypertension-associated protein in various disease states. Clin Exp Hypertens 1998;20:617–27
   PubMed Web of Science ®Google Scholar
• Ritz E, Tomaschitz A. Aldosterone and kidney: a rapidly moving frontier (an update). Nephrol Dial Transplant 2013. [Epub ahead of print]. doi: 10.1093/ndt/gft035
   Web of Science ®Google Scholar
• Fedorova OV, Shapiro JI, Bagrov AY. Endogenous cardiotonic steroids and salt-sensitive hypertension. Biochim Biophys Acta 2010;1802:1230–6
   PubMed Web of Science ®Google Scholar
• Fridman AI, Matveev SA, Agalakova NI, et al. Marinobufagenin, an endogenous ligand of alpha-1 sodium pump, is a marker of congestive heart failure severity. J Hypertens 2002;20:1189–94
   PubMed Web of Science ®Google Scholar
• Lopatin DA, Ailamazian EK, Dmitrieva RI, et al. Circulating bufodienolide and cardenolide sodium pump inhibitors in preeclampsia. J Hypertens 1999;17:1179–87
   PubMed Web of Science ®Google Scholar
• Fedorova OV, Simbirtsev AS, Kolodkin NI, et al. Monoclonal antibody to an endogenous bufadienolide, marinobufagenin, reverses preeclampsia-induced Na/K-ATPase inhibition and lowers blood pressure in NaCl-sensitive hypertension. J Hypertens 2008;26:2414–25
   PubMed Web of Science ®Google Scholar
• Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008;93:3266–81
   PubMed Web of Science ®Google Scholar
• Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005;45:1243–8
   PubMed Web of Science ®Google Scholar
• Reincke M, Fischer E, Gerum S, et al. Observational study mortality in treated primary aldosteronism: the German Conn's registry. Hypertension 2012;60:618–24
   PubMed Web of Science ®Google Scholar
• Schwartz GL. Screening for adrenal-endocrine hypertension: overview of accuracy and cost-effectiveness. Endocrinol Metab Clin North Am 2011;40:279–94, vii
   PubMed Web of Science ®Google Scholar
• Pilz S, Tomaschitz A, Stepan V, et al. Graz Endocrine Causes of Hypertension (GECOH) study: a diagnostic accuracy study of aldosterone to active renin ratio in screening for primary aldosteronism. BMC Endocr Disord 2009;9:11
   PubMedGoogle Scholar
• Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf) 2007;66:607–18
   PubMed Web of Science ®Google Scholar
• Priyadarshi S, Valentine B, Han C, et al. Effect of green tea extract on cardiac hypertrophy following 5/6 nephrectomy in the rat. Kidney Int 2003;63:1785–90
   PubMed Web of Science ®Google Scholar
• Piecha G, Koleganova N, Ritz E, et al. High salt intake causes adverse fetal programming – vascular effects beyond blood pressure. Nephrol Dial Transplant 2012;27:3464–76
   PubMed Web of Science ®Google Scholar
• Morris RK, Riley RD, Doug M, et al. Diagnostic accuracy of spot urinary protein and albumin to creatinine ratios for detection of significant proteinuria or adverse pregnancy outcome in patients with suspected pre-eclampsia: systematic review and meta-analysis. BMJ 2012;345:e4342
   PubMed Web of Science ®Google Scholar
• Huang Q, Gao Y, Yu Y, et al. Urinary spot albumin:creatinine ratio for documenting proteinuria in women with preeclampsia. Rev Obstet Gynecol 2012;5:9–15
   PubMedGoogle Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604–12
   PubMed Web of Science ®Google Scholar
• Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). The ACAPS Group. Control Clin Trials 1992;13:293–314
   PubMedGoogle Scholar
• Fuchs SC, de Mello RG, Fuchs FC. Home blood pressure monitoring is better predictor of cardiovascular disease and target organ damage than office blood pressure: a systematic review and meta-analysis. Curr Cardiol Rep 2013;15:413
   PubMedGoogle Scholar
• Bernini G, Moretti A, Orlandini C, et al. Plasma and urine aldosterone to plasma renin activity ratio in the diagnosis of primary aldosteronism. J Hypertens 2008;26:981–8
   PubMed Web of Science ®Google Scholar
• Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29–36
   PubMed Web of Science ®Google Scholar
• Fedorova OV, Talan MI, Agalakova NI, et al. Endogenous ligand of alpha(1) sodium pump, marinobufagenin, is a novel mediator of sodium chloride-dependent hypertension. Circulation 2002;105:1122–7
   PubMed Web of Science ®Google Scholar
• Hauck C, Frishman WH. Systemic hypertension: the roles of salt, vascular Na+/K + ATPase and the endogenous glycosides, ouabain and marinobufagenin. Cardiol Rev 2012;20:130–8
   PubMed Web of Science ®Google Scholar
• Anderson DE, Fedorova OV, Morrell CH, et al. Endogenous sodium pump inhibitors and age-associated increases in salt sensitivity of blood pressure in normotensives. Am J Physiol Regul Integr Comp Physiol 2008;294:R1248–54
   PubMed Web of Science ®Google Scholar
• Abramowitz J, Dai C, Hirschi KK, et al. Ouabain- and marinobufagenin-induced proliferation of human umbilical vein smooth muscle cells and a rat vascular smooth muscle cell line, A7r5. Circulation 2003;108:3048–53
   PubMed Web of Science ®Google Scholar
• Bagrov AY, Fedorova OV, Roukoyatkina NI, Zhabko EP. Effect of endogenous digoxin-like factor and digoxin antibody on myocardial Na+, K(+)-pump activity and ventricular arrhythmias in acute myocardial ischaemia in rats. Cardiovasc Res 1993;27:1045–50
   PubMed Web of Science ®Google Scholar
• Haller ST, Drummond CA, Yan Y, et al. Passive immunization against marinobufagenin attenuates renal fibrosis and improves renal function in experimental renal disease. Am J Hypertens 2014;27:603–9
   PubMed Web of Science ®Google Scholar
• Jablonski KL, Fedorova OV, Racine ML, et al. Dietary sodium restriction and association with urinary marinobufagenin, blood pressure, and aortic stiffness. Clin J Am Soc Nephrol 2013;8:1952–9
   PubMed Web of Science ®Google Scholar
• Kolmakova EV, Haller ST, Kennedy DJ, et al. Endogenous cardiotonic steroids in chronic renal failure. Nephrol Dial Transplant 2011;26:2912–19
   PubMed Web of Science ®Google Scholar
• Tomaschitz A, Pilz S, Ritz E, et al. Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J 2010;31:1237–47
   PubMed Web of Science ®Google Scholar
• Edelmann F, Tomaschitz A, Wachter R, et al. Serum aldosterone and its relationship to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction. Eur Heart J 2012;33:203–12
   PubMed Web of Science ®Google Scholar
• Purdy RE. Summary of studies of changes in vascular reactivity caused by natriuretic hormones. Clin Exp Hypertens 1998;20:705–16
   PubMed Web of Science ®Google Scholar
• Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem 2005;51:386–94
   PubMed Web of Science ®Google Scholar
• Pilz S, Kienreich K, Drechsler C, et al. Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study. J Clin Endocrinol Metab 2012;97:E75–9
   PubMed Web of Science ®Google Scholar